Home › Ischemic Stroke › NCT07599904
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements. 2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\* during treatment for acute ischemic stroke. 3. Participant is 18 years of age or older. Exclusion Criteria: 1. Participant who may be unable to complete follow-up within the registry. 2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study. 3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results based on Principal Investigator's discretion.
About the study
Post-Market Registry
What is being tested
- Mechanical Thrombectomy (device)
Sponsor: Medtronic Neurovascular Clinical Affairs · Participants: 1,500 · Started: Jul 13, 2026
Contact the study team
- Stephanie Salisbury · Phone: 612-979-7251
Official record on ClinicalTrials.gov — NCT07599904
Locations in the U.S.
| Michigan | McLaren Flint Hospital, Flint |
| New York | Buffalo General Medical Center, Buffalo |
| Texas | University of Texas Health Science Center at Houston, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.